UBS AM’s Takeda Pharmaceutical TAK Stock Holding History

UBS AM’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$899K	Hold	56,108	–	–	﹤0.01%	2374
2026 Q1	$1.04M	Buy	56,108 +45,458	+427%	+$798K	﹤0.01%	2334
2025 Q4	$166K	Buy	+10,650	New	+$152K	﹤0.01%	2479
2020 Q1	–	Sell	-22,234	Closed	-$439K	–	2523
2019 Q4	$439K	Sell	22,234 -610,180	-96%	-$11.7M	﹤0.01%	2284
2019 Q3	$10.9M	Buy	632,414 +48,654	+8%	+$841K	0.01%	928
2019 Q2	$10.3M	Sell	583,760 -54,727	-9%	-$996K	0.01%	947
2019 Q1	$13M	Buy	638,487 +225,521	+55%	+$4.54M	0.01%	856
2018 Q4	$6.95M	Buy	+412,966	New	+$6.97M	0.01%	969

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS AM's TAK Position: Q2 2026 in Review

UBS AM held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 56,108 shares worth $899K. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

UBS AM first reported a position in TAK in Q4 2018 and has held it in 8 quarters since. The position peaked at $13M in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

UBS AM held 56,108 shares of Takeda Pharmaceutical worth $899K as of Q2 2026.
UBS AM left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2374 holding.
UBS AM first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 8 quarters since.
UBS AM's Takeda Pharmaceutical position peaked at $13M in Q1 2019.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.